Senior Correspondent, London
Ben's Feed
Jul 31, 2014

AstraZeneca steps up push into cancer immunotherapy

LONDON (Reuters) – AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types.

The company is seen as No. 4 in a race to develop the first drug in a new class that fights cancer by unleashing the body’s immune system, behind rivals Roche, Merck & Co and Bristol-Myers Squibb.

Jul 31, 2014
Jul 31, 2014

AstraZeneca raises forecasts after seeing off Pfizer

LONDON (Reuters) – AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach from rival Pfizer two months ago.

Second-quarter sales and earnings both beat expectations, helped by several one-off factors, including a product-related payment from Pfizer worth $200 million.

Jul 31, 2014

AstraZeneca smashes forecasts in second quarter after seeing off Pfizer

LONDON (Reuters) – AstraZeneca (AZN.L: Quote, Profile, Research, Stock Buzz) smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion (69.7 billion pounds) takeover approach from rival drugmaker Pfizer (PFE.N: Quote, Profile, Research, Stock Buzz) two months ago.

On the back of the strong results, AstraZeneca raised its guidance for the full year, predicting sales would hold steady and not decline as previously expected.

Jul 31, 2014

AstraZeneca smashes forecasts in Q2 after seeing off Pfizer

LONDON, July 31 (Reuters) – AstraZeneca smashed
forecasts for second-quarter sales and earnings on Thursday,
demonstrating resilience after seeing off a $118 billion
takeover approach from rival drugmaker Pfizer two months
ago.

On the back of the strong results, AstraZeneca raised its
guidance for the full year, predicting sales would hold steady
and not decline as previously expected.

Jul 30, 2014
Jul 30, 2014

AstraZeneca buys Almirall lung drugs for up to $2.1 billion

LONDON, July 30 (Reuters) – AstraZeneca took a major
step to build up its respiratory medicine business on Wednesday
by striking a deal worth up to $2.1 billion to acquire the
rights to lung drugs developed by Spain’s Almirall.

The British drugmaker, which resisted a $118 billion
takeover attempt by Pfizer in May, said it would pay an
initial $875 million and up to $1.22 billion in development,
launch and sales-related milestones.

Jul 29, 2014
Jul 29, 2014
Jul 29, 2014

Despite strains, GlaxoSmithKline dividend seen safe for now

LONDON (Reuters) – GlaxoSmithKline’s fat dividend is under strain but Britain’s biggest drugmaker is likely to scrape by without cutting payouts as it seeks to compensate investors during a bumpy reshaping of the company.

Worries about GSK’s dividend, which offers a sector-beating yield of 5.5 percent, have mounted since last week when it warned on 2014 profits and confirmed plans to sell several profitable older drugs.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben